Aerocrine enters distribution agreement with Chest in Japan


Aerocrine enters distribution agreement with Chest in Japan

SOLNA - February 11, 2008 - Aerocrine AB (OMX Nordic Exchange: AERO) announces
that the company has entered into a distribution agreement with Chest M.I. Inc.
Chest will market and sell NIOX MINO® in Japan.

Chest manufactures and sells a large range of products to measure lung function
as well oxygen delivery systems for home use. The company which was founded in
1965 is one of the largest companies in its field with over 50% share of the
Japanese market. Chest has an impeccable reputation and impressive market
coverage with over 10 local sales offices. Chest will apply for market
authorization of NIOX MINO in Japan and then proceed to product launch.
 
”Chest is an ideal partner for marketing and sales of our product in Japan”,
says Paul de Potocki, CEO of Aerocrine. ”The company has established relations
and years of experience from selling medical devices to our prime target groups.
Chest has also shown an impressive knowledge and enthusiasm for our product and
method of inflammatory control.”

Eight million people suffers from asthma in Japan and the disease causes around
3000 deaths yearly, primarily due to inferior disease control. NIOX MINO is a
handheld device that in a couple of minutes gauges the inflammation in the
airways, the underlying cause of asthma. Treatment of asthma focuses primarily
on keeping the inflammation under control, which leads to fewer symptoms and
less acute asthma exacerbations.


For more information, contact:

Paul de Potocki, CEO, telephone: +46 8 629 07 82


About Aerocrine
Aerocrine AB (publ) is a medical technology concern focused on the improved
management and care of patients with airway inflammation. The company markets
NIOX® Flex globally, and also markets NIOX MINO® - which represents a new
generation of hand-held products - in Europe. Both products enable fast and
reliable management of airway inflammation and may therefore play a critical
role in more effective diagnosis, treatment and follow-up of asthma patients.
Aerocrine is based in Sweden with subsidiaries in the US, Germany and the UK.
Aerocrine shares were listed on the Stockholm Stock Exchange on 15 June, 2007.

Aerocrine may be required to disclose the information provided herein pursuant
to the Securities Markets Act. The information was submitted for publication at
8 am on February the 11th 2008.

Anhänge

GlobeNewswire